Walter & Keenan Wealth Management LLC IN ADV Sells 600 Shares of Novartis AG (NYSE:NVS)

Walter & Keenan Wealth Management LLC IN ADV decreased its stake in shares of Novartis AG (NYSE:NVS) by 14.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,550 shares of the company’s stock after selling 600 shares during the period. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Novartis were worth $345,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. CRA Financial Services LLC bought a new position in shares of Novartis during the third quarter worth approximately $215,000. Carnegie Investment Counsel increased its position in Novartis by 7.5% during the 3rd quarter. Carnegie Investment Counsel now owns 11,869 shares of the company’s stock worth $1,365,000 after buying an additional 832 shares during the period. CHICAGO TRUST Co NA lifted its holdings in shares of Novartis by 9.2% during the third quarter. CHICAGO TRUST Co NA now owns 4,304 shares of the company’s stock worth $495,000 after buying an additional 361 shares in the last quarter. Redhawk Wealth Advisors Inc. boosted its position in shares of Novartis by 12.7% in the third quarter. Redhawk Wealth Advisors Inc. now owns 11,099 shares of the company’s stock valued at $1,277,000 after acquiring an additional 1,247 shares during the period. Finally, Procyon Advisors LLC grew its stake in shares of Novartis by 4.1% in the third quarter. Procyon Advisors LLC now owns 20,873 shares of the company’s stock valued at $2,401,000 after acquiring an additional 823 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NVS. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. StockNews.com upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, BMO Capital Markets raised their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Trading Down 0.8 %

Shares of NVS stock opened at $106.17 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.90 and a current ratio of 1.04. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The company has a market cap of $217.00 billion, a PE ratio of 18.06, a P/E/G ratio of 1.70 and a beta of 0.58. The stock’s fifty day moving average price is $100.32 and its two-hundred day moving average price is $108.40.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities analysts predict that Novartis AG will post 8.42 EPS for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.